F-1: Trinity Biotech Registers $39M Secondary Offering

Trinity Biotech PLC files to register up to 55.9 million ADSs for resale by Perceptive Credit Holdings, converting existing debt into equity.

Summary

• Trinity Biotech PLC is registering up to 55,890,900 American Depositary Shares (ADSs) for resale by Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P. (the Selling Shareholders).
• These ADSs represent 1,117,818,000 Ordinary Shares, with each ADS representing 20 Ordinary Shares.
• The ADSs are issuable upon the conversion of up to $60,000,000 aggregate principal amount of a convertible promissory note and $12,500,000 of payment obligations under a conversion rights agreement.
• The conversion price is set at 97% of the volume-weighted average price (VWAP) of the ADSs at the time of conversion, subject to a floor price of $1.03 per ADS.
• The company will not receive any cash proceeds from the sale of ADSs by the Selling Shareholders; however, the conversion directly reduces the outstanding debt obligations.
• As of December 31, 2025, the company had approximately US$134.58 million in total indebtedness.
• The closing price of an ADS on The NASDAQ Global Select Market on January 14, 2026, was $0.70.

Sentiment

Score: 3

Explanation: The filing highlights substantial existing debt, negative shareholder equity, and significant potential dilution from the conversion of debt into equity. The current ADS price is below the conversion floor, suggesting further downside risk. While debt reduction is positive, the method and scale of dilution, coupled with the company's financial position, indicate a negative outlook for existing shareholders.

Positives

• Conversion of debt into equity will directly reduce the company's outstanding debt obligations.
• The company is focused on developing diabetes management solutions and human diagnostics, including continuous glucose monitoring (CGM) products, indicating a strategic direction in a growing market.

Negatives

• The secondary offering will cause substantial dilution to existing shareholders.
• Sales of ADSs by the Selling Shareholders could cause the trading price of the company's ADSs to decline.
• The company has substantial indebtedness, totaling approximately US$134.58 million as of December 31, 2025.
• The company reported negative total shareholders' equity of $(54,715) thousand as of September 30, 2025.
• The current ADS closing price of $0.70 (January 14, 2026) is below the conversion floor price of $1.03, suggesting potential for further price decline if conversions occur at market prices.

Risks

• Substantial indebtedness could impair the company's flexibility and access to capital and adversely affect its financial position.
• Inability to generate or raise sufficient funds to repay debt as it becomes due and to continue as a going concern.
• Pandemics or other public health emergencies, including ongoing effects of the COVID-19 pandemic.
• The occurrence of hostilities and political instability, including between Russia and Ukraine and between Hamas and Israel, and resulting volatility and other effects on global economic conditions.
• Changes in customer demand.
• Ability to successfully develop and commercialize new products, including new biosensor-related products and the continuous glucose monitoring (CGM) product.
• Conversion of the Conversion Obligations will cause substantial dilution to existing shareholders.
• The sale of ADSs acquired by the Selling Shareholders could cause the price of the company's ADSs to decline.
• Uncertainty regarding the actual number of ADSs to be issued under the Conversion Documents at any one time or in total.
• The sale of a substantial number of ADSs by the Selling Shareholders, or anticipation of such sales, could make it more difficult for the company to sell equity or equity-related securities in the future.

Future Outlook

The company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. It also highlights the need to raise capital in one or more debt or equity offerings to satisfy or refinance obligations and fund operations, with no assurance of success or acceptable terms.

Industry Context

Trinity Biotech operates in the commercial stage biotechnology sector, specifically focusing on diabetes management solutions and human diagnostics, including wearable biosensors like continuous glucose monitoring (CGM) products. This places the company in a competitive and evolving market driven by technological advancements in diagnostics and increasing demand for chronic disease management tools. The development of CGM products aligns with a broader industry trend towards personalized and continuous health monitoring.

Corporate Governance

Related Party Transactions

• Perceptive Credit Holdings II, L.P. (PCH II) and Perceptive Credit Holdings III, L.P. (PCH III) are the Selling Shareholders and are involved in the Convertible Note and Conversion Rights Agreement.
• PCH III is the Administrative Agent for the Sixth Amended and Restated Credit Agreement.
• The company has issued warrants and ADSs to Perceptive funds in previous unregistered sales related to credit agreements and acquisitions.

Stakeholder Impact

• Shareholders will experience substantial dilution due to the conversion of debt into equity. The potential sale of a large number of ADSs by selling shareholders could depress the share price.
• Creditors (Perceptive funds) will convert a portion of their debt into equity, reducing their credit exposure and potentially gaining upside if the stock performs well, but also taking on equity risk.
• The company reduces its debt burden, improving its balance sheet, but at the cost of significant equity dilution. This could free up cash flow otherwise used for debt service.
• Employees, customers, and suppliers may indirectly benefit from a potentially stronger balance sheet due to debt reduction, which could provide more stability for operations, product development, and commercialization efforts.

Next Steps

• The registration statement needs to become effective before the securities can be sold.
• Selling Shareholders may sell the ADSs from time to time after the registration statement becomes effective.
• The company is obligated to keep the registration statement effective until all shares are disposed of or become freely tradable under Rule 144 (after December 22, 2026).
• The company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product.

Key Dates

Recommendation

The filing reveals a company with substantial debt and negative shareholder equity, indicating a precarious financial position. The secondary offering, resulting from the conversion of significant debt into equity, will cause substantial dilution to existing shareholders. With the current ADS price ($0.70) below the conversion floor price ($1.03), there's a strong likelihood of further downward pressure on the stock as selling shareholders convert and potentially offload shares. The need for future capital raises, coupled with the existing financial strain and dilution risk, suggests a challenging outlook for equity holders.

Keywords

Trinity Biotech, TRIB, Secondary Offering, ADS, American Depositary Shares, Convertible Note, Debt Conversion, Dilution, Biotechnology, Diagnostics, Diabetes Management, Continuous Glucose Monitoring, CGM, SEC Filing, F-1, Perceptive Credit Holdings